| 6.085 0.015 (0.25%) | 09-14 14:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.04  |
1-year : | 8.85 |
| Resists | First : | 6.88 |
Second : | 7.57 |
| Pivot price | 6.65 |
|||
| Supports | First : | 5.76 |
Second : | 4.8 |
| MAs | MA(5) : | 6.3 |
MA(20) : | 6.71 |
| MA(100) : | 5.68  |
MA(250) : | 5.62 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 9.8 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 9.75 | Low : | 2.99 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NUVB ] has closed above bottom band by 0.2%. Bollinger Bands are 12.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.4 - 6.44 | 6.44 - 6.48 |
| Low: | 5.84 - 5.9 | 5.9 - 5.95 |
| Close: | 5.99 - 6.07 | 6.07 - 6.13 |
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Wed, 02 Sep 2026
Nuvation Bio to Participate in Upcoming Investor Conferences - PR Newswire
Mon, 31 Aug 2026
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Fri, 21 Aug 2026
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Tue, 18 Aug 2026
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know - Yahoo Finance
Thu, 06 Aug 2026
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Thu, 30 Jul 2026
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 350 (M) |
| Shares Float | 264 (M) |
| Held by Insiders | 18.4 (%) |
| Held by Institutions | 68 (%) |
| Shares Short | 53,220 (K) |
| Shares Short P.Month | 55,670 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | -88.2 % |
| Operating Margin | -161.1 % |
| Return on Assets (ttm) | -12.4 % |
| Return on Equity (ttm) | -47.9 % |
| Qtrly Rev. Growth | 555.5 % |
| Gross Profit (p.s.) | 0.42 |
| Sales Per Share | 0.48 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -121 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -13.74 |
| PEG Ratio | 0 |
| Price to Book value | 8.28 |
| Price to Sales | 12.45 |
| Price to Cash Flow | -17.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|